A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Gastric CancerGastric AdenocarcinomaGastroEsophageal Cancer
Interventions
DRUG

DKN-01 300mg

Administered by IV infusion

DRUG

DKN-01 600mg

Administered by IV infusion

DRUG

DKN-01 400mg

Administered by IV infusion

DRUG

Tislelizumab 200mg

Administered by IV infusion

DRUG

Tislelizumab 400mg

Administered by IV infusion

DRUG

Oxaliplatin

Administered by IV infusion

DRUG

Capecitabine 1000mg/ m2 twice daily (BID)

Administered orally

DRUG

Leucovorin Calcium

Administered by IV infusion

DRUG

Fluorouracil

Administered by IV infusion

Trial Locations (48)

3080

Seoul National University Hospital, Seoul

3722

Severance Hospital, Yonsei University Health System, Seoul

6351

Samsung Medical Center, Seoul

6591

The Catholic University of Korea St. Mary's Hospital, Seoul

10032

Columbia University Irving Medical Center, New York

10408

National Cancer Center, Goyang

13353

Charité Universitätsmedizin Berlin, Berlin

13520

CHA Bundang Medical Center, Seongnam-si

13620

Seoul National University Bundang Hospital, Seongnam

14068

Hallym University Sacred Heart Hospital, Anyang

15355

Korea University Ansan Hospital, Ansan-si

16247

The Catholic University of Korea St. Vincent's Hospital, Suwon

19111

Fox Chase Cancer Center, Philadelphia

20249

Hämatologisch-Onkologische Praxis Eppendorf (HOPE), Hamburg

21565

Gachon University Gil Medical Center, Incheon

22332

Inha University Hospital, Incheon

27710

Duke University Medical Center, Durham

32224

Mayo Clinic Florida, Jacksonville

32804

AdventHealth Cancer Institute, Orlando

49201

Dong-A University Hospital, Busan

53792

University of Wisconsin Carbone Cancer Center, Madison

60488

Institut Fur Klinisch Onkologische Forschung Am Krankenhaus Nordwest, Frankfurt

60611

Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago

60637

University of Chicago, Chicago

66113

Caritas Klinikum Saarbrücken St. Theresia, Saarbrücken

69120

Universitatsklinikum Heidelberg, Heidelberg

70433

Pontchartrain Cancer Center, Covington

74078

Slk-Kliniken, Heilbronn

77030

MD Anderson Cancer Center, Houston

85054

Mayo Clinic Cancer Center, Phoenix

85724

University of Arizona, Tucson

88212

Studienzentrum Onkologie Ravensburg, Ravensburg

90025

The Angeles Clinic Research Institute - A Cedars-Sinai Affiliate, Los Angeles

90033

University of Southern California, Los Angeles

90095

UCLA, Los Angeles

91010

City of Hope, Duarte

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

92868

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

94158

University of California San Francisco, San Francisco

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

02903

Rhode Island Hospital, Providence

02841

Korea University Anam Hospital, Seoul

04763

Hanyang University Hospital, Seoul

05505

Asan Medical Center, Seoul

07061

Boramae Hospital SNU, Seoul

08308

Korea University Guro Hospital, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BeiGene

INDUSTRY

lead

Leap Therapeutics, Inc.

INDUSTRY